Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Medicina (B.Aires) ; 66(supl.2): 16-21, 2006. tab, ilus
Artigo em Espanhol | LILACS | ID: lil-480133

RESUMO

The central role of the immune system is the preservation of the health against several pathogenic microbes and injury agents. However, on special conditions defensive mechanisms triggered towards the foreign agent can damage the host. Clinical and experimental evidence indicate that inflammatory reaction triggered by the main components of Shiga toxin (Stx)-producing Escherichia coil (STEC), participate in the evolution to the complete form of HUS. When children are diagnosed of HUS, they present evidence that have suffered a very strong and early inflammatory response. These features include: the presence of a marked neutrophilia, the polymorfonuclear leucocytes (PMN) are "deactivated or exhausted" and the monocytes are differentiated towards an inflammatory phenotype (CD14-reduced and CD16-enhanced membrane expression). In addition, HUS-patients show a marked reduction in the absolute and relative number of leucocytes carrying the receptor (CX3CR1) for the chemokine "Fractalkine" (FKN, CX3CL1), which are the classic monocytes and Natural Killer cells (NK). All these cells express a high cytotoxic potencial. The chemokine FKN is expressed in endothelial and epithelial renal cells, and is involved in the pathogenic mechanism of different nephropathies. Noteworthy, we found a significant correlation between the severity of the renal damage (as days of anuria) and the alterations described above. Finally, the protective role of specific immune response, mainly through the antibody production with Stx-neutralizing capacity, is discussed.


Assuntos
Humanos , Animais , Ratos , Síndrome Hemolítico-Urêmica/imunologia , Imunidade Inata/imunologia , Ativação de Neutrófilo/imunologia , Toxina Shiga/toxicidade , Antígenos CD/imunologia , /imunologia , Citocinas/imunologia , Modelos Animais de Doenças , Infecções por Escherichia coli/imunologia , Escherichia coli/imunologia , Escherichia coli/patogenicidade , Fatores de Crescimento de Fibroblastos/imunologia , Síndrome Hemolítico-Urêmica/terapia , Células Matadoras Naturais/imunologia , Murinae , Neutrófilos/imunologia , Diálise Renal , Toxina Shiga/antagonistas & inibidores , Toxina Shiga/imunologia
2.
Medicina (B.Aires) ; 66(supl.2): 33-36, 2006.
Artigo em Espanhol | LILACS | ID: lil-480136

RESUMO

Cattle are recognized as the major reservoir of STEC and the source of infection for human beings. Until recently, intervention strategies to decrease the contamination of meat products have been focused on the slaughter plant with the application of practices to reduce the contamination and proliferation of STEC. This has now changed following the development of intervention strategies in the farm. This could be one of the most important points of intervention to lower the incidence of human infection. Vaccines, probiotics, bacteriophages, and changes in production practices may be useful as strategies to control EHEC in the cattle. The application of such intervention measures could be difficult due to the fact that this zoonotic agent rarely causes disease in bovines. The HUS is endemic in Argentina, and the factors leading to this epidemiological situation remain unknown. However, intervention strategies undoubtedly will contribute to reduce the incidence of this zoonosis.


Assuntos
Humanos , Animais , Bovinos , Reservatórios de Doenças/microbiologia , Infecções por Escherichia coli/prevenção & controle , /patogenicidade , Proteínas de Bactérias , Bacteriófagos/imunologia , Infecções por Escherichia coli/imunologia , /virologia , Proteínas de Escherichia coli/genética , Proteínas de Escherichia coli/uso terapêutico , Vacinas contra Escherichia coli/uso terapêutico , Síndrome Hemolítico-Urêmica/imunologia , Síndrome Hemolítico-Urêmica/prevenção & controle , Lactobacillus acidophilus , Fosfoproteínas/genética , Fosfoproteínas/uso terapêutico , Probióticos/uso terapêutico , Toxina Shiga/biossíntese , Toxina Shiga/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA